Compare Adaptive Biotechnologies Corp (ADPT) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Occidental Petroleum Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.98 (market cap $4.05B), while Occidental Petroleum Corporation trades at $58.93 (market cap $55.89B). The key difference: Occidental Petroleum Corporation is far larger — about 13.8× Adaptive Biotechnologies Corp's market cap, and Occidental Petroleum Corporation pays a 2% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | OXY | |
|---|---|---|
Market Cap | $4.05B | $55.89B |
Sector | Health | Energy |
52-Week High | $25.45 | $66.24 |
52-Week Low | $12.30 | $38.92 |
Enterprise Value | $4.12B | $74.65B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Occidental Petroleum (OXY) trades at $55.91, down 0.23% today, with a bullish technical outlook supported by moving averages and a consensus price target of $69.25. Recent Q2 2026 earnings of $2.40 per share beat expectations, driven by higher oil prices and strong cash flow, while the company focuses on debt reduction and targets over $4 billion in sustainable cash flow by 2030.
OXY presents a buy opportunity with solid profitability and growth prospects, but faces risks from oil price volatility and competitive pressures. Analysts are optimistic, with 50% recommending buy, though investors should monitor execution on cash flow targets and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
